An Australian fund manager has increased its stake to 19.61% in the company.
() has had one of its major shareholders, Merchant Funds Management, increase its stake to 19.61% from 18.61%.
The increase was the result of a series of on-market trades, the most recent being the purchase of 1 million shares last Thursday 16 May for $145,478.
Merchant is a boutique Perth-based fund manager focused on early-stage ASX opportunities.
READ: CannPal Animal Therapeutics files new patent application as industry-leading research is recognised
The buying activity from Merchant follows purchases from a number of CannPal board members.
The most recent purchase was from founder and managing director Layton Mills who purchased 65,000 shares via on-market trades earlier this month.
The share purchase from Mills follows purchases from Max Johnston in March, chairman Geoff Starr in February, and Robert Clifford in January.
CannPal is a pharmaceutical-focused animal health company researching the benefits of medical cannabis for companion animals such as dogs and cats.
CPAT-01 is the company’s lead drug candidate under development targeting pain and inflammation control in dogs.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of CannPal Animal Therapeutics Ltd named herein, including the promotion by the Company of CannPal Animal Therapeutics Ltd in any Content on the...
FOR OUR FULL DISCLAIMER CLICK HERE